Background: The aim of this study was to determine the relationship between the severity of bladder functions, fatigue, quality of life (QoL), fall, and pelvic floor muscle strength in patients with Multiple Sclerosis (PwMS).
Methods: Patients were divided into two groups according to their Expanded Disability Status Scale (EDSS) bladder scores as Group 1 (EDSS bladder score 0-1, mildly affected group, n = 25) and Group 2 (EDSS bladder score 2-3-4, moderate and severely affected group, n = 21). Pelvic floor muscle (PFM) strength (EMG-Biofeedback device), fear of fall (Fall Efficacy Scale (FES-1)), fatigue (Fatigue Severity Scale (FSS)), QoL (Urogenital Distress Inventory-short form (UDI-6), and Incontinence Impact Questionnaire-short form (IIQ-7)) were evaluated.
Results: 46 female patients diagnosed with MS were included in this study. No significant differences in baseline characteristics were seen between the groups except age. EDSS bladder score were 1 (0-1) and 3 (2-4), EMG-Biofeedback score were 79,5 ± 8,11 and 41,7 ± 5,48, FSS score were 38,7 ± 2,80 and 54±2,20, FES-I score were 16,9 ± 2,15 and 40,2 ± 7,39, UDI-6 score were 4,24±0,47 and 8,42±0,64, IIQ-7 score were 3,64±0,86 and 18,2 ± 1,42 in Group 1 and Group 2. As a result of statistical analysis, significant differences were found in less fatigue and fall, higher PFM strength and better QoL with mildly affected PwMS (p<0,05).
Conclusion: There was a significant difference in terms of bladder function level in PFM strength, fall, fatigue and QoL between the mildly affected group and the moderate and severely affected group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2023.105013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies.
Front Immunol
January 2025
Department of Neurology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Objective: To investigate the differences of clinical characteristics and treatment outcomes between paraneoplastic neurologic syndrome (PNS) patients with one high-risk antibody and patients with two high-risk antibodies.
Methods: We retrospectively analyzed the data of 51 PNS patients with high-risk antibody. Clinical data were extracted from the patients' electronic medical records.
The impact of bladder symptoms on Relapsing Remitting Multiple Sclerosis patients' Quality of Life - a pilot study.
Wiad Lek
December 2024
DEPARTMENT OF NEUROLOGY, FACULTY OF MEDICAL SCIENCES IN KATOWICE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND.
Objective: Aim: Bladder disorders are one of the most troubling symptoms of Multiple Sclerosis (MS), which impact patients quality of life (QoL). Therefore the aim of this pilot study was to assess this problem.
Patients And Methods: Materials and Methods: 47 patients (28 females and 19 males, aged 40,8±12,2 years; EDSS 3,2±1,9) diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS) during disease modifying treatment (DMT) were enrolled to our study.
Role of detrusor overactivity and interval between bladder sensations on the severity of overactive bladder symptoms in patients with multiple sclerosis.
Fr J Urol
December 2024
GRC 01, GREEN Group of clinical REsEarch in Neurourology, Sorbonne University, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France.
Purpose: This study aimed to assess the relationship between kinetics of bladder sensations perception, detrusor overactivity (DO), and severity of overactive bladder (OAB) symptoms in patients with multiple sclerosis (PwMS).
Methods: All PwMS who underwent urodynamic assessment including three cystometries (20mL/min, 100mL/min, and 100mL/min with 4°C fluid) between June 2020 and October 2022 were included in this retrospective study. Data collected were bladder diaries, symptoms assessed with Urinary Symptom Profile (USP), bladder sensations with first desire to void (FDV) and strong desire to void (SDV) during the 20mL/min cystometry, and presence of DO.
Impact of Siponimod on Clinical and Radiological Parameters of Secondary Progressive Multiple Sclerosis: A Real-World Prospective Study.
J Clin Neurol
November 2024
Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- Siponimod is being studied for its potential to treat active secondary progressive multiple sclerosis (SPMS) in a year-long clinical trial involving 50 patients.
- Over the 12-month follow-up, significant improvements were seen, including reductions in annual relapse rates, the number of gadolinium-enhanced lesions, and fatigue levels.
- The treatment successfully maintained stable cognitive and physical disability statuses, indicating its overall efficacy for SPMS patients, including those with higher initial disability scores.
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
Ther Adv Neurol Disord
October 2024
Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Article Synopsis
- - Patients with multiple sclerosis (PwMS) face a higher risk of infections, especially those treated with ocrelizumab (OCR), as shown in a study involving 6,155 patients over a median period of 3.7 years.
- - Serious infections (SIs) were reported at an incidence rate of 1.50 per 100 patient years for relapsing MS and 3.70 for progressive MS, with lower respiratory, urinary, abdominal, gastrointestinal, and skin infections being the most common.
- - Significant risk factors for SIs included comorbidities, recent relapses, and higher disability scores, particularly in patients with progressive MS where a high EDSS score indicated a fourfold increase in
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!